Clinical Trial Update: A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Zipalertinib in advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion or other uncommon EGFR mutations is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Zipalertinib (Zipalertinib)

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations | Phase 2 | Status: RECRUITING